Physician profile
Manar Abdalla
NPI 1700632411
$2,584.04
in general payments reported to CMS, 2019-2025
34 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,139 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $299.23 | 2024-2025 | Ozempic, Rybelsus |
| Ardelyx, INC. | $267.84 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $199.15 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $151.19 | 2024-2025 | Airsupra |
| Abbvie INC. | $134.71 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $121.79 | 2024-2025 | |
| Scilex Pharmaceuticals INC. | $121.65 | 2024-2025 | |
| Alpha Cognition USA, INC. | $107.37 | 2025 | Zunveyl |
| Lilly USA, LLC | $105.53 | 2024-2025 | Mounjaro, Kisunla, Zepbound |
| Kowa Pharmaceuticals America, INC. | $99.26 | 2025 | Zoryve |
| Sumitomo Pharma America, INC. | $93.54 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.94 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $78.57 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $76.38 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Ucb, INC. | $73.50 | 2024 | Briviact |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manar Abdalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.